CT 2106
Alternative Names: PG camptothecin; PG-CPT; Polyglutamate camptothecinLatest Information Update: 21 Jul 2008
At a glance
- Originator Cell Therapeutics
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 06 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society for Clinical Oncology (ASCO-2006) have been added to the adverse events and pharmacokinetics sections
- 14 Dec 2004 Phase-II clinical trials in Ovarian cancer in Europe (IV)
- 22 Apr 2004 Phase-I/II clinical trials in Colorectal cancer in USA (IV)